EMBECTA CORP. (EMBC) Gross Margin
- Gross margin · 12 months: Value 59.03%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 59.03% | Gross profit / revenue. Period ending 2026-06-30. $601.30M ÷ $1.02B × 100 ≈ 59.03% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 601.30M USD | Gross Profit |
| Revenue | 1.02B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 417.40M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $601.30M | $1.02B | $417.40M | 59.03% |
| 2026-03-31 | $645.10M | $1.04B | $397.40M | 61.88% |
| 2025-12-31 | $681.40M | $1.08B | $398.30M | 63.11% |
| 2025-09-30 | $676.80M | $1.08B | $403.60M | 62.64% |
| 2025-06-30 | $692.10M | $1.10B | $410.40M | 62.78% |
| 2025-03-31 | $685.10M | $1.08B | $394.40M | 63.46% |
| 2024-12-31 | $706.40M | $1.11B | $401.30M | 63.77% |
| 2024-09-30 | $735.20M | $1.12B | $387.90M | 65.46% |
| 2024-06-30 | $743.20M | $1.12B | $375.70M | 66.42% |
| 2024-03-31 | $742.60M | $1.13B | $389.90M | 65.57% |
| 2023-12-31 | $747.00M | $1.12B | $375.40M | 66.55% |
| 2023-09-30 | $749.90M | $1.12B | $370.90M | 66.91% |
| 2023-06-30 | $745.00M | $1.11B | $368.50M | 66.91% |
| 2023-03-31 | $758.40M | $1.12B | $360.10M | 67.81% |
| 2022-12-31 | $759.80M | $1.12B | $356.10M | 68.09% |
| 2022-09-30 | $774.90M | $1.13B | $354.60M | 68.61% |
| 2022-06-30 | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) |
| 2021-09-30 | $800.40M | $1.17B | $364.90M | 68.69% |
| 2021-06-30 | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) |
| 2020-09-30 | $762.60M | $1.09B | $322.90M | 70.25% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |